Logo

New Products: LifeCodexx's PraenaTest

Jun 25, 2014
Premium

LifeCodexx is now offering three options for its next-gen sequencing-based noninvasive fetal aneuploidy test, PraenaTest. The standard option includes testing for trisomies 21, 18, and 13. One option includes testing for only trisomy 21. An expanded option includes testing for trisomies 21, 18, and 13, as well as the determination of fetal gonosomal aneuploidy for singleton pregnancies, such as Turner, Triple X, Klinefelter, and XYY syndromes. In addition, starting in 2015, patients will be able to be refunded by their statutory health insurances for a trial period.

Filed under

Clinical Sequencing
Sequencing
Diagnostics
Next-Generation Sequencing
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.